Construction of a Multimodal Intelligence Fusion-Based Model for Predicting Neoadjuvant Therapy Sensitivity in Muscle-Invasive Bladder Cancer Preoperatively

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500107558

Enrollment

Unknown

Registered

2025-08-14

Start date

2025-09-01

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle-Invasive Bladder Cancer

Interventions

Neoadjuvant Therapy Non-responders:NA

Neoadjuvant Therapy Responders:NA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Voluntarily signed informed consent form; 2. Age >= 18 years; 3. Received medical care at Nanfang Hospital, Southern Medical University between January 2020 and January 2028; 4. Histopathologically confirmed diagnosis of bladder cancer; 5. Underwent neoadjuvant therapy for bladder cancer; 6. Completed prostate-specific imaging and laboratory studies (e.g., ultrasound, MRI, CT) within 3 months prior to bladder cancer surgery;

Exclusion criteria

Exclusion criteria: 1. Poor-quality radiographic imaging data; 2. Incomplete or missing medical records; 3. Received multiple regimens of neoadjuvant therapy for bladder cancer; 4. Deemed ineligible for participation by the Principal Investigator;

Design outcomes

Primary

Measure	Time frame
AUC;sensitivity;specificity;	—

Countries

China

Contacts

Public ContactZaosong Zheng

Southern Medical University Southern Hospital

zhengzaosong@smu.edu.cn+86 20 6278 7210

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026